ArticleMarine drugs2017
Asperentin B, a New Inhibitor of the Protein Tyrosine Phosphatase 1B.
Article in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Differences in Metabolite Profiles and Bioactivities of Intra-Strain Variants of Marine FungusMetabolites · 2025Article
- Recent advances in the structures and bioactivities of benzopyrans derived from marine fungi: a review.Frontiers in pharmacology · 2024Review
- Secondary Metabolites, Biological Activities, and Industrial and Biotechnological Importance ofMarine drugs · 2023Review
- New Bioactive β-Resorcylic Acid Derivatives from the Alga-Derived FungusMarine drugs · 2023Article
- Recent advances in the discovery, biosynthesis, and therapeutic potential of isocoumarins derived from fungi: a comprehensive update.RSC advances · 2023Review
- Potential Therapeutic Target Protein Tyrosine Phosphatase-1B for Modulation of Insulin Resistance with Polyphenols and Its Quantitative Structure-Activity Relationship.Molecules (Basel, Switzerland) · 2022Article
- Recent advances in PTP1B signaling in metabolism and cancer.Bioscience reports · 2021Review
- Review
- Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases.Foods (Basel, Switzerland) · 2020Review
- New Monoterpenoids and Polyketides from the Deep-Sea Sediment-Derived FungusMarine drugs · 2020Article
- Dihydroisocoumarins produced by Diaporthe cf. heveae LGMF1631 inhibiting citrus pathogens.Folia microbiologica · 2020Article
- Antimicrobial Secondary Metabolites from the Seawater-Derived FungusMolecules (Basel, Switzerland) · 2019Article
- PTP1B negatively regulates nitric oxide-mediated Pseudomonas aeruginosa killing by neutrophils.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the frame of studies on secondary metabolites produced by fungi from deep-sea environments we have investigated inhibitors of enzymes playing key roles in signaling cascades of biochemical pathways relevant for the treatment of diseases. Here we report on a new inhibitor of the human protein tyrosine phosphatase 1B (PTP1B), a target in the signaling pathway of insulin. A new asperentin analog is produced by an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.